STOCK TITAN
  1. Home
  2. News
  3. GERN

Geron to Present at the Stifel Virtual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

FOSTER CITY, Calif.--()--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, will present a company overview at the Stifel Virtual Healthcare Conference on Tuesday, November 17, 2020 at 2:40 p.m. ET.

A live audio webcast of the presentation will be available on Geron’s website, www.geron.com/investors/events. If you are unable to listen to the live presentation, an archived webcast will be available on the Company’s website for 30 days.

About Geron

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.

Contacts

Suzanne Messere
Investor and Media Relations
investor@geron.com
media@geron.com

Stock GERN logo
Geron Corp

NASDAQ:GERN

GERN Rankings

#1850 Ranked by Market Cap
#3292 Ranked by Stock Gains
N/A Ranked by Dividends

GERN Latest News

May 2, 2024
Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights
Apr 25, 2024
Geron to Announce First Quarter 2024 Financial Results on May 2, 2024
Apr 18, 2024
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 3, 2024
Geron to Participate at Upcoming Investor Conferences in April
Mar 19, 2024
Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

GERN Stock Data

2.18B
475.07M
0.09%
67.83%
7.93%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
FOSTER CITY

About GERN

we are a biopharmaceutical company developing first-in-class therapies for cancer. imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. imetelstat is a potent and specific inhibitor of telomerase. based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or mf, myelodysplastic syndromes, or acute myelogenous leukemia.